Target intelligence / Profile preview

HILPDA antisense RNA 1 (HILPDA-AS1)

Target
HILPDA-AS1
Molecular classification
Long non-coding RNA, lncRNA
01

Overview

HILPDA antisense RNA 1 (HILPDA-AS1) is a long non-coding RNA (lncRNA) gene affiliated with the antisense class of RNA molecules. It is transcribed from the DNA strand opposite to the protein-coding HILPDA gene. Like other antisense lncRNAs, HILPDA-AS1 is presumed to regulate the expression of its sense counterpart (HILPDA), potentially through mechanisms such as transcriptional interference, RNA-RNA hybrid formation, or chromatin remodeling, although direct functional studies have not been reported. No evidence suggests HILPDA-AS1 is itself a direct therapeutic target, nor has it been described as a drug target, disease biomarker, or safety concern. The gene is cataloged in reference databases (Ensembl: ENSG00000240758, HGNC: 55641). If you intended to refer to the protein-coding gene HILPDA (Hypoxia-inducible lipid droplet-associated protein), that is a distinct protein involved in lipid metabolism and disease, and is considered a therapeutic target in metabolic disease and cancer contexts[1][4][5][6][8], but HILPDA-AS1 itself is a non-coding RNA gene, not a protein or established therapeutic target.

02

Mechanism of action

Not established

03

Biological functions

Not fully characterizedMay regulate gene expression of the HILPDA sense gene or other lociPotentially influences mRNA stabilityPotentially influences chromatin statePotentially influences transcriptional activityPresumed to regulate the expression of its sense counterpart (HILPDA)Potential mechanism: transcriptional interferencePotential mechanism: RNA-RNA hybrid formationPotential mechanism: chromatin remodeling
04

Disease associations

Unknown at present; no explicit data linking HILPDA-AS1 itself to specific disease phenotypes

Beyond the preview

Go deeper on HILPDA antisense RNA 1 (HILPDA-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HILPDA antisense RNA 1 (HILPDA-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call